Comparative Prognostic Value of the Durie–Salmon, ISS, and mSMART Staging Systems in Multiple Myeloma
Eurasian Journal of Medical Advances · 2026 · 6 (2) · 62-68
DOI: 10.14744/ejma.268062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medical Advances, 2026. Verfasst von Engin Hendem und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
Multiple myeloma (MM) is a plasma cell malignancy characterized by marked interpatient variability in clinical course and prognosis. Accurate staging systems are essential for risk stratification and survival prediction. We aimed to compare the prognostic performance of the Durie–Salmon (DS), International Staging System (ISS), and Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) systems in predicting overall survival.
Methods
This retrospective study included 110 patients diagnosed with MM at a tertiary hematology center. Patients were staged according to the DS, ISS, and mSMART systems. Overall survival (OS) was evaluated using the Kaplan–Meier method, and prognostic factors were evaluated using univariate and multivariate Cox regression analyses.
Results
Advanced disease stages were significantly associated with poorer overall survival across all staging systems (Durie–Salmon, p
Zitieren
APA
Hendem, E., & Ayer, M. (2026). Comparative Prognostic Value of the Durie–Salmon, ISS, and mSMART Staging Systems in Multiple Myeloma. Eurasian Journal of Medical Advances, 6(2), 62-68. https://doi.org/10.14744/ejma.268062
Vancouver
Hendem E, Ayer M. Comparative Prognostic Value of the Durie–Salmon, ISS, and mSMART Staging Systems in Multiple Myeloma. Eurasian Journal of Medical Advances. 2026;6(2):62-68. doi:10.14744/ejma.268062
BibTeX
@article{Hendem2026,
author = {Hendem, Engin and Ayer, Mesut},
title = {Comparative Prognostic Value of the Durie–Salmon, ISS, and mSMART Staging Systems in Multiple Myeloma},
journal = {Eurasian Journal of Medical Advances},
year = {2026},
volume = {6},
number = {2},
pages = {62--68},
doi = {10.14744/ejma.268062}
}
EUVIMED